News
THTX
1.300
-4.41%
-0.060
Weekly Report: what happened at THTX last week (0415-0419)?
Weekly Report · 3d ago
Theratechnologies Announces Virtual Annual Meeting
TipRanks · 04/16 01:06
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies Inc. Has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024. The company is a biopharmaceutical company focused on the development and commercialization of innovative therapies.
Barchart · 04/15 15:15
Weekly Report: what happened at THTX last week (0408-0412)?
Weekly Report · 04/15 12:23
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Inc. Is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Paul Lévesque will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference is taking place April 16-17 in Toronto.
Barchart · 04/11 06:30
THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024
Theratechnologies reported earnings per share of -10 cents for the first quarter of 2024. The company reported revenue of $16.25 million. This was 19.17% worse than the analyst estimate of $20.10 million for the same period. Theratechnological reported results for the second quarter of 2016.
Investorplace · 04/10 15:52
Theratechnologies Inc reports results for the quarter ended in February - Earnings Summary
Theratechnologies Inc reports results for the quarter ended in February. The company reported a quarterly adjusted loss of 10 cents per share. Revenue fell 18.4% to $16.25 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 04/10 13:31
Theratechnologies’ Q1 Financials and Oncology Advances
TipRanks · 04/10 12:07
Theratechnologies Q1 EPS $(0.10) Beats $(0.12) Estimate, Sales $16.25M Miss $20.10M Estimate
Theratechnologies reported quarterly losses of $0.10 per share and sales of $16.25 million. The company beat the analyst consensus estimate by 16.67%. The company also reported a 77.27 percent increase in sales from the same period last year.
Benzinga · 04/10 11:32
Theratechnologies GAAP EPS of -$0.10 beats by $0.04, revenue of $16.2M misses by $3.19M
Seeking Alpha · 04/10 11:32
*Theratechnologies 1Q Loss/Shr 10c >THTX
Dow Jones · 04/10 11:31
*Theratechnologies Sees FY24 Rev $87M-$90M >THTX
Dow Jones · 04/10 11:31
THERATECHNOLOGIES INC: FY2024 REVENUE GUIDANCE CONFIRMED BETWEEN $87 AND $90 MLN AND AN ADJUSTED EBITDA IN RANGE OF $13-15 MLN
Reuters · 04/10 11:30
THERATECHNOLOGIES INC <TH.TO> Q1 REV VIEW $20.1 MLN -- LSEG IBES DATA
Reuters · 04/10 11:30
THERATECHNOLOGIES OUTLOOK FY REVENUE USD 87-90 MILLION
Reuters · 04/10 11:30
*Theratechnologies 1Q Rev $16.2M >THTX
Dow Jones · 04/10 11:30
Earnings Scheduled For April 10, 2024
Delta Air Lines is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion. Altamira Therapeutics is estimated to report earnings for its Fiscal Year 2023. Rent the Runway and Root are also expected to report after the bell.
Benzinga · 04/10 09:18
Theratechnologies: Fiscal Q1 Earnings Snapshot
Montreal-based company reported a loss of $4.5 million in its fiscal first quarter. Theratechnologies Inc. Posted revenue of $16.2 million in the period. The metabolic disorder drug company says it lost 10 cents per share in the quarter.
Barchart · 04/10 07:21
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. Reports business highlights and financial results for the first quarter of fiscal year 2024 ended February 29, 2024. The company is a biopharmaceutical company focused on the development and commercialization of innovative therapies. All figures are in US dollars unless otherwise stated.
Barchart · 04/10 06:30
Theratechnologies Presents Preclinical Data That Highlight Versatility And Flexibility Of SORT1+ Technology Platform
Benzinga · 04/08 20:35
More
Webull provides a variety of real-time THTX stock news. You can receive the latest news about Theratechnologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About THTX
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.